2 products found

XILIS, Inc. products

Xilis - MicroOrganoSphere (MOS) Technology

Xilis’ proprietary MicroOrganoSphere (MOS) technology represents a new standard in patient-derived micro-tumor production. From each patient, MOS retains unique patient tissue structure, genetic alterations, gene expression, immune microenvironment and histopathology. Overcoming major limitations of widely used, yet limited, models including xenografts and organoids, MOS offers unprecedented speed, scalability, and predictivity in a small-scale model, opening up tremendous opportunities using patient-derived micro-tumors in drug development and discovery as well as drug prioritization assays for patients.

MicroOrganoSphere - Precision Oncology

Xilis’ MicroOrganoSphereTM powers the only assay which can provide oncologists with accurate results of drug sensitivity on a patient’s own tumor within the clinical decision-making window - finally realizing the promise of precision medicine. Xilis is developing a panel of disease specific assays systematically testing the most important standard-of-care drugs within equipoise or difficult-decision settings to help clinicians and their patients make the most appropriate treatment decision for their unique cancer in a timely manner.